Located in London, UK, King's Health Partners has deployed the Oncology Research Information System (ORIS), an informatics platform that consolidates translational medicine data from multiple sites into one system. Based on the IDBS Enterprise Translational Medicine Solution, a product that supports cross-organisation translational medicine research, ORIS will help uncover new avenues for research into cancer causes and personalised treatments to improve patient outcomes.
The initial ORIS deployment allows King’s Health Partners to combine clinical, genetic and tissue sample data across more than 26,000 historic breast cancer patients, alongside a current feed of new, consented patients’ data direct from the clinic into the longitudinal research database. The platform can identify patient cohorts – with similar disease characteristics – whose treatment, genetic profiles and outcomes can be followed while retaining complete patient confidentiality.
‘ORIS is the ideal environment for us to advance our translational medicine studies to better understand the complex causes and molecular basis of cancer,’ said Professor Peter Parker, head of the Division of Cancer Studies and R&D lead for the Integrated Cancer Centre at King’s Health Partners. ‘By making better use of patient data across our partnership, ORIS will actively and positively impact patient care in the development of innovative cancer treatments and prognostics.’
